噻托溴铵联合奥达特罗预防慢阻肺急性加重(DYNAGITO):双盲随机平行组阳性对照试验
DYNAGITO 试验在 51 个国家 818 个中心纳入 7880 例有急性加重史的慢阻肺患者,1:1 随机接受噻托溴铵-奥达特罗 5 μg-5 μg 或噻托溴铵 5 μg 每日一次,治疗 52 周。联合治疗中重度急性加重发生率低于噻托溴铵单药(RR 0·93,99% CI 0·85-1·02;p=0·0498),但未达到预设的 0·01 显著性水平;两组不良事件报告比例相似。
要点
- 联合治疗中重度急性加重发生率数值上低于单药,但未达预设显著性水平
- 两组不良事件报告比例相似
- 对有急性加重史的慢阻肺患者,联合治疗未达预期疗效
核心结论
- 噻托溴铵联合奥达特罗相比噻托溴铵单药未如预期那样降低急性加重率。
研究设计与样本
- 52 周双盲、随机、平行组、阳性对照试验,1:1 随机分组,采用随机区组设计。
- 7880 例有急性加重史的慢阻肺患者,平均年龄 66·4 岁(SD 8·5),5626 例(71%)为男性,平均 FEV1 占预计值 44·5%(SD 27·7)。
- 3939 例接受噻托溴铵-奥达特罗 5 μg-5 μg 每日一次,3941 例接受噻托溴铵 5 μg 每日一次;使用吸入性糖皮质激素者继续该治疗。
主要发现
- 中重度急性加重发生率联合治疗低于噻托溴铵单药(RR 0·93,99% CI 0·85-1·02;p=0·0498),未达到预设的 0·01 显著性水平。
- 两组报告不良事件的患者比例相似。
关键数值与推荐
- 主要终点为从首次用药至末次给药后 1 天的中重度慢阻肺急性加重发生率。
- 主要分析纳入所有随机分组并接受至少一剂研究药物、且不属于因现场方案违例被排除中心的患者。
临床怎么用
- 对接受噻托溴铵单药治疗仍有急性加重史的慢阻肺患者,加用奥达特罗的获益未达到预设显著性标准,决策需结合个体情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Combinations of long-acting bronchodilators are recommended to reduce the rate of chronic obstructive pulmonary disease (COPD) exacerbations. It is unclear whether combining olodaterol, a long-acting beta-agonist, with tiotropium, a long-acting anti-muscarinic, reduces the rate of exacerbations compared with tiotropium alone. METHODS: This 52-week, double-blind, randomised, parallel-group, active-controlled trial randomly assigned (1:1) patients with COPD with a history of exacerbations using a randomised block design to receive tiotropium-olodaterol 5 μg-5 μg or tiotropium 5 μg once daily. Patients using inhaled corticosteroids continued this therapy. Treatment was masked to patients, investigators, and those involved in analysing the data. The primary endpoint was the rate of moderate and severe COPD exacerbations from the first dose of medication until 1 day after last drug administration. The primary analysis included all randomly assigned patients who received any dose of study medication but were not from a site excluded due to on-site protocol violations. The trial is registered with ClinicalTrials.gov, number NCT02296138. FINDINGS: Overall, 9009 patients were screened from 818 centres in 51 countries. We recruited 7880 patients between Jan 22, 2015 and March 7, 2016 (mean age 66·4 years [SD 8·5], 5626 [71%] were men, mean FEV1 percent predicted 44·5% [SD 27·7]): 3939 received tiotropium-olodaterol and 3941 tiotropium. The rate of moderate and severe exacerbations was lower with tiotropium-olodaterol than tiotropium (rate ratio [RR] 0·93, 99% CI 0·85-1·02; p=0·0498), not meeting the targeted 0·01 significance level. The proportion of patients reporting adverse events was similar between treatments. INTERPRETATION: Combining tiotropium and olodaterol did not reduce exacerbation rate as much as expected compared with tiotropium alone. FUNDING: Boehringer Ingelheim International GmbH.
引用
- Calverley PMA, Anzueto AR, Carter K, et al. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial. Lancet Respir Med. 2018. PMID: 29605624. doi:10.1016/S2213-2600(18)30102-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。